Abstract
Thioridazine (TDZ) has been shown to have in vitro activity against multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of Mycobacterium tuberculosis, to promote the killing of intracellular MDR and XDR strains and to cure the mouse of antibiotic-susceptible and -resistant pulmonary tuberculosis (TB) infections. Recently, TDZ was used to cure 10 of 12 XDR-TB patients in Buenos Aires, Argentina. At the time of writing, it is being used for the therapy of non-antibiotic-responsive terminal XDR-TB patients in Mumbai, India, on the basis of compassionate therapy and although it is too early to determine a cure, the patients have improved appetite, weight gain, are afebrile and free of night sweats, and their radiological picture shows great improvement. Because XDR-TB is essentially a terminal disease in many areas of the world and no new effective agents have yet to yield successful clinical trials, global clinical trials for the therapy of XDR-TB are urgently required. (C) 2010 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
| Original language | English |
|---|---|
| Pages (from-to) | 524-526 |
| Number of pages | 3 |
| Journal | International Journal of Antimicrobial Agents |
| Volume | 35 |
| Issue number | 6 |
| Early online date | 25 Feb 2010 |
| DOIs | |
| Publication status | Published - Jun 2010 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Pulmonary tuberculosis
- Multidrug-resistant TB
- Extensively drug-resistant TB
- NEW-YORK-CITY
- MYCOBACTERIUM-TUBERCULOSIS
- EMERGENCE
Fingerprint
Dive into the research topics of 'Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now!'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver